Highbridge Capital Management’s Myriad Genetics MYGN Stock Holding History

Highbridge Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-36,513	Closed	-$701K	–	1485
2017 Q1	$701K	Buy	36,513 +8,317	+29%	+$147K	0.01%	758
2016 Q4	$470K	Buy	28,196 +1,704	+6%	+$30.8K	0.01%	792
2016 Q3	$545K	Sell	26,492 -92,983	-78%	-$2.36M	0.01%	752
2016 Q2	$3.66M	Buy	+119,475	New	+$4.15M	0.06%	322
2015 Q1	–	Sell	-6,751	Closed	-$230K	–	1524
2014 Q4	$230K	Buy	+6,751	New	+$240K	﹤0.01%	1032
2013 Q4	–	Sell	-1,035,508	Closed	-$24.3M	–	1243
2013 Q3	$24.3M	Buy	1,035,508 +285,315	+38%	+$8.11M	0.26%	113
2013 Q2	$20.2M	Buy	+750,193	New	+$21.7M	0.2%	124

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Highbridge Capital Management's MYGN Position: Q2 2017 in Review

Highbridge Capital Management sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 36,513 shares — an estimated $701K sold.

Highbridge Capital Management first reported a position in MYGN in Q2 2013 and held it in 7 quarters. The position peaked at $24.3M in Q3 2013. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

Highbridge Capital Management reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 36,513 Myriad Genetics shares in Q2 2017, an estimated $701K.
Highbridge Capital Management first reported a position in Myriad Genetics in Q2 2013 and held it in 7 quarters.
Highbridge Capital Management's Myriad Genetics position peaked at $24.3M in Q3 2013.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.